Nonclinical model for assessing gastric effects of bisphosphonates

Digestive Diseases and Sciences

Volumn 42, Issue 2, 1997, Pages 281-288

  Blank, Marion A ^a   Ems, Beth L ^a   Gibson, George W ^a   Myers, William R ^a   Berman, S Kim ^a   Phipps, Roger J ^a   Smith, Paige N ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

amino bisphosphonate; calcium chelation; gastric damage; indomethacin; pyridinyl bisphosphonate; rat

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; EDETIC ACID; EGTAZIC ACID; INDOMETACIN; NE 97221; PAMIDRONIC ACID; RISEDRONIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG STRUCTURE; HISTOPATHOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STOMACH LESION; SUBCUTANEOUS DRUG ADMINISTRATION;

ALENDRONATE; ANIMALS; CHELATING AGENTS; DIPHOSPHONATES; EDETIC ACID; EGTAZIC ACID; ETIDRONIC ACID; INDOMETHACIN; MALE; RATS; RATS, SPRAGUE-DAWLEY; STOMACH;

EID: 0031040990     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018849415297     Document Type: Article

References (12)

1. Geddes AD, D'Souza SM, Ebetino FH, Ibbotson KJ: Bisphosphonates: Structure-activity relationships and therapeutic implications. In Bone and Mineral Research. Volume 8. JNM Heersche, JA Kanis (eds). Amsterdam, Elsevier Science, 1994, pp 265-306
2. Fleisch H: Bisphosphonates in Bone Disease. Berne, Stampfli and Co., 1993
3. Adami S, Mian M, Gatti P, Rossini M, Zamberlan N, Bertoldo F, Lo Cascio V: Effects of two oral doses of alendronate in the treatment of Paget's disease of hone. Bone 15:415-417, 1994
4. Fitton A, McTavish D: Pamidronate: A review of its pharmacological properties and therapeutic efficacy in resorptive hone disease. Drugs 41:289-318, 1991
5. Maconi G, Blanchi Porro G: Multiple ulcerative esophagitis caused by alendronate. Am J Gastroenterol 90:1889-1890, 1995
6. Lufkin EG, Argueta R, Whitaker MD, Cameron AL, Wong VH, Egan KS, O'Fallon WM, Riggs BL: Pamidronate: An unrecognized problem in gastrointestinal tolerability. Osteoporos Int 4:320-322, 1994
7. Black DM, Reiss TF, Nevitt MC, Cauley J, Karpf D, Cummings SR: Design of the fracture intervention trial. Osteoporos Int Suppl 3:S29-S39, 1993
8. Wallace JL, McCafferty DM, Carter L, McKnight W: Tissue-selective inhibition of prostaglandin synthsis in rat by tepoxalin: Anti-inflammatory without gastropathy? Gastroenterology 105:1630-1636, 1993
9. Glavin GB: Calcium channel modulators: Effects on gastric function. Eur J Pharmacol 160:323-330, 1989
10. Ebrahimpour A, Ebetino FH, Sethuraman G, Nancollas GH: Determination of solubility and calcium ion stability constants of a phosphonoalkylphosphinate (PAP) and bisphosphonates such as EHDP, risedronate, alendronate, 3-pic AMBP, and 3-pic AMPMP. In Mineral Scale Formation and Inhibition. Z Amjad (ed). New York, Plenum Press, 1995, pp 295-305
11. Cioli V, Silvestrini B, Dordoni F: Evaluation of the potential of gastric ulceration after administration of certain drugs. Exp Mol Pathol 6:68-83, 1967
12. Silen W: Experimental models of gastric ulceration and injury. Am J Physiol 255:G395-G402, 1988